Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/13732

Target Organs and Levels of Evidence for TR-328

Toxicology and Carcinogenesis Studies of Methyl Carbamate (CASRN 598-55-0) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Methyl carbamate
598-55-0		 08/19/1986 Gavage
R: 0,100,200, M: 0,500,1000 MG/KG/50 PER GROUP		 BioReliance, Inc

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: NEOPLASTIC NODULE 3/50 0/50 3/49; CARCINOMA 1/50 0/50 4/49
Non-Neoplastic Lesions
  • HARDERIAN GLAND: INFLAMMATION 4/50 11/50 16/50
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: NEOPLASTIC NODULE 0/50 0/50 5/49; CARCINOMA 0/50 0/50 1/50
Non-Neoplastic Lesions
  • HARDERIAN GLAND: INFLAMMATION 7/50 16/50 30/50
Male Mice: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • LUNG: HYPERPLASIA, ADENOMATOUS 13/50 19/50 24/49; HISTIOCYTOSIS 11/50 7/50 21/49
Female Mice: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • LUNG: HYPERPLASIA, ADENOMATOUS 7/49 10/50 18/50; HISTIOCYTOSIS 9/49 10/50 21/50